Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma

Brain and Central Nervous System Tumors Clinical Trial

Official title:

A Prospective Randomised Controlled Trial Of Hyperfractionated Versus Conventionally Fractionated Radiotherapy In Standard Risk Medulloblastoma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00053872
• Other study ID #: CDR0000269521
• Secondary ID: SIOP-PNET-4EU-20
• Status: Active, not recruiting
• Phase: Phase 3
• First received: February 5, 2003
• Last updated: June 23, 2014
• Start date: February 2003

Study information

• Verified date: February 2007
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving radiation therapy in different ways with combination chemotherapy may kill any remaining tumor cells following surgery. It is not yet known which radiation therapy regimen combined with combination chemotherapy is more effective in treating medulloblastoma.

PURPOSE: Randomized phase III trial to compare different radiation therapy regimens plus combination chemotherapy in treating children who have undergone surgery for medulloblastoma.

Description:

OBJECTIVES:

• Compare the event-free survival rate in pediatric patients with standard-risk medulloblastoma treated with conventional vs hyperfractionated radiotherapy and vincristine followed by maintenance with cisplatin, lomustine, and vincristine.

• Compare the overall survival of patients treated with these regimens.

• Compare the pattern of relapse, especially local relapse (tumor bed or posterior fossa outside tumor bed), in patients treated with these regimens.

• Determine the toxicity of surgery and whether there are identifiable factors that correlate with toxicity in these patients.

• Determine the impact of any surgical complications on commencement of adjuvant therapy and event-free survival of these patients.

• Compare late sequelae, in terms of health status, endocrine deficiencies, and hearing loss, in patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to country. Patients are randomized to 1 of 2 treatment arms.

• Arm I: Within 28-40 days after surgical resection, patients undergo conventional fractionated radiotherapy once daily, 5 days a week, for 6-7 weeks. Patients also receive vincristine IV once weekly for 8 weeks.

• Arm II: Beginning as in arm I, patients undergo hyperfractionated radiotherapy twice daily, 5 days a week, for 6-7 weeks. Patients also receive vincristine as in arm I.

• Maintenance chemotherapy:Six weeks after completion of radiotherapy, all patients receive cisplatin IV over 6 hours and oral lomustine on day 1 and vincristine IV on days 1, 8, and 15. Treatment repeats every 6 weeks for 8 courses.

Patients are followed at least every 6 months for 3 years.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 316 patients (158 per treatment arm) will be accrued for this study within 4 years.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 316
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 3 Years to 21 Years

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed medulloblastoma, including the following variants:

• Classic

• Nodular/desmoplastic

• Large cell

• Melanotic

• Medullomyoblastoma

• Prior total or subtotal surgical removal of tumor within the past 28-40 days

• No more than 1.5 cm^2 residual tumor by early postoperative MRI or CT scan

• No brainstem or supratentorial primitive neuroectodermal tumor

• No atypical teratoid rhabdoid tumor

• No known predisposition to medulloblastoma (e.g., Gorlin's syndrome)

• No CNS metastasis (supratentorial, arachnoid of the posterior fossa, or craniospinal axis) by MRI

• No clinical evidence of metastasis outside the CNS

• No tumor cells in lumbar cerebrospinal fluid by cytospin

PATIENT CHARACTERISTICS:

Age

• 3 to 21

Performance status

• Not specified

Life expectancy

• Not specified

Hematopoietic

• Hematological function less than CTC grade 2

Hepatic

• Liver function less than CTC grade 2

Renal

• Renal function less than CTC grade 2

Other

• Not pregnant

• Fertile patients must use effective contraception

• Able to receive radiotherapy twice daily

• Vital functions within age-appropriate normal range

• Audiological function less than CTC grade 2

• No medical contraindication to radiotherapy or chemotherapy

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• Not specified

Endocrine therapy

• Concurrent dexamethasone as an antiemetic allowed, provided all other therapies have failed

Radiotherapy

• No concurrent cobalt irradiation

Surgery

• See Disease Characteristics

Other

• No prior treatment for brain tumor or any other malignancy

Study Design

Allocation: Randomized, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Brain and Central Nervous System Tumors
• Central Nervous System Neoplasms
• Medulloblastoma
• Nervous System Neoplasms

Intervention

Drug:
• cisplatin

• lomustine

• vincristine sulfate

Procedure:
• adjuvant therapy

Radiation:
• radiation therapy

Locations

Country	Name	City	State
Belgium	U.Z. Gasthuisberg	Leuven
France	Institut Curie Hopital	Paris
Germany	Universitaets - Kinderklinik Wuerzburg	Wuerzburg
Italy	Ospedale Infantile Regina Margherita	Turin
Netherlands	Academisch Medisch Centrum at University of Amsterdam	Amsterdam
Spain	Hospital de Cruces	Vizcaya
Sweden	Ostra Sjukhuset	Gothenburg
United Kingdom	Royal Liverpool Children's Hospital, Alder Hey	Liverpool	England

Sponsors (1)

Lead Sponsor	Collaborator
University of Leicester

Countries where clinical trial is conducted

Belgium,  France,  Germany,  Italy,  Netherlands,  Spain,  Sweden,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparison of event-free survival at 3 years			No
Secondary	Comparison of overall survival			No
Secondary	Comparison of the pattern of relapse (i.e., local relapse [tumor bed and posterior fossa outside tumor bed])			No
Secondary	Comparison of late sequelae, in terms of health status, quality of life, hearing loss, and endocrine deficiencies			No
Secondary	Toxicity of neurosurgery			Yes